Notable ETF Outflow Detected - IXJ, SYK, DHR, MDT
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 03 2025
0mins
Source: NASDAQ.COM
Current Share Price Analysis: IXJ's current share price is $85.32, which is between its 52-week low of $80.681 and high of $101.305, indicating a potential area for technical analysis using the 200-day moving average.
ETFs Trading Dynamics: Exchange traded funds (ETFs) function similarly to stocks, with units that can be created or destroyed based on investor demand, affecting the underlying holdings and market flows significantly.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SYK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SYK
Wall Street analysts forecast SYK stock price to rise
20 Analyst Rating
17 Buy
3 Hold
0 Sell
Strong Buy
Current: 299.460
Low
390.00
Averages
430.32
High
465.00
Current: 299.460
Low
390.00
Averages
430.32
High
465.00
About SYK
Stryker Corporation is a medical technology company. It offers products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Its segments include MedSurg and Neurotechnology and Orthopaedics. Its MedSurg products include surgical equipment, patient and caregiver safety technologies, and navigation systems (Instruments), endoscopic and communications systems (Endoscopy), and patient handling, emergency medical equipment, intensive care disposable products and clinical communication and artificial intelligence-assisted virtual care platform technology (Medical). Neurotechnology includes neurosurgical, neurovascular and craniomaxillofacial implant products. Its Orthopaedics primarily include implants used in total joint replacements, such as hip, knee and shoulder, and others. It offers solutions for venous thromboembolism clot removal without the use of thrombolytic drugs. It is also focused on treating calcified arterial disease.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Product Innovation: Stryker has launched the TPX HD small bone power tool, specifically designed to meet the demands of complex orthopaedic surgeries, particularly in total joint revisions and minimally invasive procedures, enhancing surgical performance and control.
- Design Advantages: The tool features a tapered attachment design that improves visibility in confined spaces, while its housing effectively acts as a barrier against motor heat at high speeds, ensuring surgical safety during operations.
- Enhanced User Experience: With a shorter handpiece length and improved grip, the TPX HD provides greater comfort for surgeons, particularly in high-precision revision surgeries, thereby increasing trust in the tool's reliability.
- Market Impact: By introducing the TPX HD, Stryker further solidifies its leadership in the medical technology sector, expected to impact the treatment outcomes of over 150 million patients globally, driving growth in the orthopaedic market.
See More
- Performance Enhancement: Stryker's newly launched TPX HD small bone power tool delivers up to 296% more torque and 40% faster performance at high speeds, significantly enhancing surgical efficiency and precision in complex procedures.
- Design Optimization: The tool features a tapered attachment design that improves visibility in confined spaces, while a shorter handpiece length and improved grip enhance ergonomics, ensuring surgeons can trust and control the tool during critical moments.
- Customizable Control: Enabled by I.D. Touch software within Stryker's CORE™ 2 Console, surgeons can tailor drill response and sensitivity to their preferences, thereby increasing flexibility and adaptability during surgeries.
- Versatile Attachments: The TPX HD comes with multiple attachment lengths and a PROStep™ 5:1 reducer, capable of cutting and removing metal and bone cement, further expanding its application range in orthopaedic surgeries.
See More
- Cyber Attack Incident: Israeli researchers have identified that Iranian hackers executed a disruptive cyberattack on the Los Angeles County Metropolitan Transportation Authority (LACMTA) in March, stealing at least 700GB of emails and backup files, which led to parts of the network being shut down, although train and bus operations remained unaffected, customer service was disrupted.
- Hacker Group Background: The hacker group known as Ababil claimed responsibility for the attack, with its name referencing a bombing incident in the Iranian city of Minab, raising suspicions of its potential ties to the Iranian state and reinforcing the view of it as a proxy for Iranian espionage.
- Investigation and Response: Gambit Security, a cybersecurity firm, has alerted relevant authorities about its findings, while the FBI stated it is coordinating a response to the incident, although the Los Angeles transit authority has not commented on the investigation's results.
- Ongoing Cyber Threats: Since the onset of the U.S. and Israel's war against Iran in late February, Iranian hackers have been launching frequent cyberattacks across various sectors, including medical devices and infrastructure, indicating a sustained enhancement of their cyber capabilities and a significant threat to critical infrastructure.
See More
- European Launch: Stryker's introduction of the Pangea Plating System in Europe aims to treat a wide range of fracture patterns, marking a significant expansion in the trauma care sector that is expected to enhance market share and brand influence.
- Successful Clinical Application: Prof. Alex Trompeter and his team at St. George's University Hospital in London completed the first clinical case in Europe, demonstrating the system's effectiveness in real surgical settings and validating its practical design philosophy.
- Global Collaborative Development: The Pangea portfolio was developed in collaboration with 26 orthopedic surgeons worldwide, incorporating global anatomical data to ensure applicability across diverse patient populations, thereby enhancing surgical flexibility and efficiency.
- Surgical Workflow Optimization: The system is designed to simplify operating room procedures and adapt to various fracture patterns, which is expected to improve surgeons' workflows and enhance patient treatment outcomes.
See More
- Dividend Growth Strategy: Trivariate Research emphasizes that in turbulent markets, investors should focus on companies with consistent dividend growth over the past five years for downside protection, especially as traditional defensive stocks now represent just over 10% of the S&P 500's market cap.
- Rollins Performance: Pest control company Rollins recently raised its dividend by over 10% to 18 cents per share, and despite a roughly 10% decline in its stock in 2026, analysts remain optimistic about its ability to deliver compounding growth, with Goldman Sachs reiterating a buy rating.
- Cheniere Energy Growth: Liquefied natural gas company Cheniere Energy increased its quarterly dividend by over 10% last October, currently yielding 0.9%, and its stock has risen 26% this year, benefiting from reduced LNG production in the Middle East.
- Analyst Support: Cheniere Energy's first-quarter results exceeded expectations, raising its adjusted EBITDA guidance to between $7.25 billion and $7.75 billion, with analysts bullish on its strong volume outlook and project execution, as 23 out of 24 analysts rate it a buy.
See More
- Acquisition Scale: Stryker's acquisition of Amplitude Vascular Systems for up to $835 million marks a significant milestone in expanding its peripheral vascular portfolio, expected to enhance its market position in treating calcified peripheral arterial disease.
- Technological Innovation: Amplitude's next-generation hydraulic intravascular lithotripsy platform offers a new solution for treating calcified peripheral arterial disease, potentially improving patient outcomes and strengthening Stryker's competitive edge in the medical technology sector.
- Strategic Partnership Background: Venture capital firm BioStar Capital served as an early strategic growth partner for Amplitude, providing IP licensing, initial startup capital, and guidance through various development phases and clinical studies, showcasing a robust support network for the startup.
- Future Outlook: Despite recent cyber incidents, Stryker maintains its 2026 outlook of 8%-9.5% organic sales growth and adjusted EPS of $14.90-$15.10, indicating confidence in future growth and adaptability in the market.
See More








